Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1999-09-02
2000-06-20
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544118, 544262, A61K 31519, C07D48704
Patent
active
060778415
ABSTRACT:
The invention is directed to novel substituted 5-heterocyclyl pyrazolopyrimidinones and derivatives thereof, their synthesis and their use in treating sexual dysfunction in mammals, especially male erectile dysfunction. Pharmaceutical compositions containing the compounds and methods of using them to treat sexual dysfunction are also described.
REFERENCES:
patent: 4666908 (1987-05-01), Hamilton
patent: 5250534 (1993-10-01), Bell et al.
patent: 5294612 (1994-03-01), Bacon et al.
patent: 5346901 (1994-09-01), Bell et al.
J. Org. Chem. vol. 40 No. 19; Tam Huynh-Dinh, annie Kolb, Catherine Gouyette and Jean Igolen; Synthesis of C Nucleosides.X1 Structural Analogs of Formycin B; pp. 2825-2830 (1975).
J. Med. Chem; Harriet W. Hamilton Daniel F. Ortwine, Donald F. Worth, and James A. Bristol; Synthesis and Structure--Activity Relatioships of Pyrazolo[4,3-d]pyrimidin-7-One as Adenosine Receptor Antagonists; vol. 30; pp. 91-96 (1987).
J. Med. Chem.; C. Subramanyam et al; 6-(4-Pyridinyl)-H-1,2,3-Triazolo{4,5-D]-Pyrimidin-4 (5h)--One: A Structurally Novel Competitive AMPA Receptor Antagonist; vol. 38; pp. 587-589 (1995).
Guan Jihua
Macielag Mark J.
Sui Zhihua
Appollina Mary
Janssen Pharmaceutica N.V.
Patel Sudhaker B.
Shah Mukund J.
LandOfFree
5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1853869